Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pharmaniaga Bhd's 3-Year RORE % for the quarter that ended in Jun. 2026 was 93.15%.
The industry rank for Pharmaniaga Bhd's 3-Year RORE % or its related term are showing as below:
XKLS:7081's 3-Year RORE % is ranked better than 91.89% of 111
companies
in the Medical Distribution industry
Industry Median: 6.23
vs XKLS:7081: 93.15
Pharmaniaga Bhd (XKLS:7081) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pharmaniaga Bhd 3-Year RORE % Related Terms
Pharmaniaga Bhd 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7081 vs MCK, COR, CAH: 3-Year RORE % Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Pharmaniaga Bhd (XKLS:7081) has a 3-Year RORE % of 93.15 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pharmaniaga Bhd and its competitors. According to the industry distribution chart, Pharmaniaga Bhd ranks #9 out of 111 companies in the Medical Distribution industry, placing it in the top 8.1%.
Is Pharmaniaga Bhd's 3-Year RORE % too high?
Pharmaniaga Bhd's current 3-Year RORE % is 93.15. The Medical Distribution industry median 3-Year RORE % is 6.23. Pharmaniaga Bhd's value of 93.15 is 1395.2% above this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #9 out of 111 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmaniaga Bhd has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's 3-Year RORE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #9 out of 111 companies for 3-Year RORE %. This places Pharmaniaga Bhd in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 6.23. Pharmaniaga Bhd's value of 93.15 is 1395.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 6.23, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current 3-Year RORE % of 93.15 is 1395.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 6.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current 3-Year RORE % is 93.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Fairly Valued. The stock's GF Value™ is RM1.12, compared to a current price of RM1.16 — trading 3.6% above its estimated fair value. The current 3-Year RORE % is 93.15 and 1395.2% above the Medical Distribution industry median of 6.23. Pharmaniaga Bhd's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current 3-Year RORE % is 93.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.16 is trading 3.6% above its estimated GF Value™ of RM1.12.
GuruFocus considers Pharmaniaga Bhd to be Fairly Valued.
Key valuation signals for XKLS:7081:
3-Year RORE %: 93.15
GF Value™: RM1.12 vs. price of RM1.16 (3.6% above fair value)
Industry Position: 1395.2% above the Medical Distribution median (#9 of 111)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
67GF Score
Get the complete analysis for XKLS:7081
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
